Chemotherapy for advanced gallbladder cancer (GBC): a systematic review and meta-analysis
AffiliationMedical Oncology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge
MetadataShow full item record
AbstractBackground: The benefit from chemotherapy, specifically for patients with gallbladder cancer (GBC), has been poorly explored since GBC is mostly studied jointly with other biliary tract cancers (BTC). Methods: Eligible studies reporting outcome of palliative systemic chemotherapy for advanced GBC were identified through MEDLINE, cross-referencing and conferences (PROSPERO-CRD42019155745). Meta-analysis of proportions and calculation of pooled weighted means were performed. Results: 58 eligible studies (n = 1,986 patients); cisplatin/gemcitabine (33% of patients), gemcitabine/oxaliplatin (14%) or gemcitabine monotherapy (9%). Estimated pooled overall radiological response rate(ORR), and pooled weighted mean progression-free (PFS) and overall survivals (OS) were 23.2% (95%-CI 20.0-26.5) (I2: 52.5% (p < 0.001)), 4.8 months (95%-CI 4.3-5.2) and 8.3 months (95%CI 7.6-8.9), respectively. Patients with non-GBC BTCs achieved a lower ORR than GBC [odds ratio 0.65 (95% CI, 0.50-0.84)]. Conclusions: GBC benefit from chemotherapy differs from other BTCs, with shorter PFS/OS despite higher ORR; new treatment options are urgently required for management of advanced GBC.
CitationAzizi AA, Lamarca A, McNamara MG, Valle JW. Chemotherapy for Advanced Gallbladder Cancer (GBC): A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology. 2021 Apr;103328.
JournalCritical Reviews in Oncology/ Hematology
- Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
- Authors: Ying J, Chen J
- Issue date: 2019 Jul
- Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
- Authors: Dierks J, Gaspersz MP, Belkouz A, van Vugt JLA, Coelen RJS, de Groot JWB, Ten Tije AJ, Meijer WG, Pruijt JFM, van Voorthuizen T, van Spronsen DJ, Rentinck M, Ten Oever D, Smit JM, Otten HM, van Gulik TM, Wilmink JW, Groot Koerkamp B, Klümpen H
- Issue date: 2018 Jun
- Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial.
- Authors: Goetze TO, Bechstein WO, Bankstahl US, Keck T, Königsrainer A, Lang SA, Pauligk C, Piso P, Vogel A, Al-Batran SE
- Issue date: 2020 Feb 14
- Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
- Authors: Sun TT, Wang JL, Fang JY
- Issue date: 2013
- A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
- Authors: Graham JS, Boyd K, Coxon FY, Wall LR, Eatock MM, Maughan TS, Highley M, Soulis E, Harden S, Bützberger-Zimmerli P, Evans TR
- Issue date: 2016 Mar 12